Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929387 | 0.87 | NOTUM (0.49) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL928907 | 0.78 | HTR2C (0.43) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| Hydrochloric Acid SCHEMBL941711 | 0.77 | HTR2C (0.42) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL929001 | 0.76 | ALDH1A1 (0.42) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL930645 | 0.75 | HTR2A (0.47) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL929817 | 0.75 | PNMT (0.44) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL2625800 | 0.75 | NOTUM (0.49) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL930670 | 0.72 | DRD1 (0.46) | HTR2AHTR2CHTR2BBIRC2 | |
| SCHEMBL12905311 | 0.72 | NOTUM (0.47) | HTR2AHTR2CHTR2BPARP1PARP10 | |
| SCHEMBL12049080 | 0.70 | NOTUM (0.48) | HTR2AHTR2CHTR2BPARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-2247590-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2010-11-10 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | GRM5, GRIK5, GRK5 | HTR2A 463/4885HTR2C 264/4885HTR2B 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.